Sign In
Buy BEAM
$25.52
-0.97 (-3.66%)
At Close: Jul 31, 2026
2 Supercharged Growth Stocks That Could Make You Richer
03:45pm, Saturday, 15'th Jul 2023
Innovation-oriented growth companies, while risky, can deliver life-altering returns on capital for patient investors. Beam Therapeutics and Nano-X Imaging are angling to upend the status quo for mult
Beam Therapeutics: Base Editing Leader With Major Catalyst Next Year
08:00am, Saturday, 20'th May 2023
Beam is a leader in base editing and has strong lab data. It has a huge amount of cash and a major deal with Pfizer.
Beam Therapeutics to Participate in Upcoming May Investor Conferences
06:30am, Wednesday, 17'th May 2023
CAMBRIDGE, Mass., May 17, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that mana
Cathie Wood Is Loading Up on These 3 Stocks Down 70% or More. Should You?
05:50am, Tuesday, 16'th May 2023
Cathie Wood's Ark Invest ETFs added to their positions recently in two biotech stocks and one telehealth stock. All three stocks have plunged over the past couple of years.
Beam Therapeutics to Participate in RBC Capital Markets 2023 Global Healthcare Conference
06:30am, Thursday, 11'th May 2023
CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Gius
Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Tops Revenue Estimates
09:09am, Wednesday, 10'th May 2023
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.33 per share versus the Zacks Consensus Estimate of a loss of $1.36. This compares to loss of $1.01 per share a year ago.
7 Best Cathie Wood Stocks for Your May 2023 Buy List
12:25pm, Tuesday, 02'nd May 2023
Cathie Wood invests in speculative stocks that don't always pan out, as 2022 showed. The chief of Ark Investment Management watched her firm outperform in 2021, though last year saw a sharp decelerati
3 Growth Stocks Cathie Wood Just Bought That Could Be Absolute Game-Changers
05:53am, Tuesday, 02'nd May 2023
Beam Therapeutics is a pioneer in base editing, an especially promising type of gene editing. CRISPR Therapeutics could soon bring the first CRISPR gene-editing therapy to market.
The 3 Most Promising Gene Editing Stocks to Buy in 2023
04:51pm, Friday, 28'th Apr 2023
Gene editing stocks are one of the hottest sectors in medicine today. Genes are the foundation of life, and from creating new organisms to curing incurable diseases, the editing of genes can bring rad
3 Stocks to Watch in April: Is it Time to Buy?
03:47pm, Tuesday, 18'th Apr 2023
Heading toward the midway point of the year, the unique dynamics associated with the post-pandemic new normal sets the stage for certain stocks to watch. That is, brewing fundamental and technical fac
7 Top Growth Stocks to Buy for the Next Decade
07:00am, Tuesday, 18'th Apr 2023
A the market returns it's time to look for the best growth stocks to buy. successful investing strategy partially requires an ability to predict the future.
Cathie Wood Loads Up On Biotech Stocks — Continues To Raise Stake In Coinbase Global
12:15am, Thursday, 06'th Apr 2023
Cathie Wood-led ARK Investment Management raised stakes in a number of biotech companies on Wednesday with these stocks recording negative returns over the last one month, potentially making them attr
7 Biotech Stocks to Buy for Breakthrough Treatments and Cures
08:54pm, Wednesday, 29'th Mar 2023
While it's a common conspiracy theory – and comedic punchline – that medical innovators only seek to manage problems rather than cure them, the reality is that several biotech stocks to buy underg
Beam Therapeutics to Participate in the Barclays 2023 Global Healthcare Conference
06:30am, Wednesday, 15'th Mar 2023
CAMBRIDGE, Mass., March 15, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Gi
3 CRISPR Gene Editing Stocks to Consider for Ground-Floor Investing
12:13pm, Monday, 06'th Mar 2023
The 2022 Nobel Prize in Chemistry went to Emmanuelle Charpentier and Jennifer Doudna for their work on developing tools to change the genetic code of living cells, tools called CRISPR/Cas. Yet long be
